Navigation Links
CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
Date:6/1/2008

- Data presented at the 2008 ASCO Annual Meeting -

- Conference call to be hosted Wednesday, June 4 at 9:00 a.m. EDT to

discuss results -

BRANFORD, Conn., June 1 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today presented encouraging results from the ongoing Phase I/II study of CR011-vcMMAE for the treatment of unresectable Stage III or Stage IV melanoma. The results were presented by Dr. Patrick Hwu, Co-Principal Investigator, and Professor, Chairman, Dept. of Melanoma Medical Oncology at The University of Texas, M.D. Anderson Cancer Center.

"In this heavily pretreated group of patients with primarily Stage IV disease, the observation of dose-dependent objective responses, tumor shrinkage, and encouraging early progression-free rate at 12 weeks at doses in the anticipated active range, leads us to believe that CR011-vcMMAE could be a potentially useful treatment for patients with advanced melanoma," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "Based on these promising results in melanoma we have expanded the CR011-vcMMAE development program to include a Phase II trial in metastatic breast cancer, and are also exploring additional doses and schedules to further optimize the activity of this antibody-drug conjugate."

As of April 4, 2008, forty patients were treated in this first-in-man Phase I/II study including a total of 32 patients in the Phase I dose-escalation portion of the trial that aimed to identify the safety and maximum tolerated dose (MTD) of CR011-vcMMAE and 8 patients in the ongoing Phase II portion of the study. During Phase I, doses of CR011-vcMMAE between 0.03 mg/kg to 2.63 mg/kg were evaluat
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... plc (NYSE: AGN ) a leading global pharmaceutical company, ... of Allergan, will provide an overview and update of the ... in New York, NY . ... will take place on Thursday, September 17, 2015 at 10:35 ... East 42nd Street, New York, NY ...
(Date:9/4/2015)... , Sept. 4, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, today announced it has ... the U.S. Food and Drug Administration (FDA) of 2015, ... now pending at the FDA to twenty-nine. ... Company, commented, "We believe our current pipeline of twenty-nine ...
(Date:9/4/2015)... Sep. 04, 2015 ... the addition of the "Veterinary Pharmaceutical Submissions ... 2015)" conference to their offering. ... all of the constituent parts of the application ... for which a marketing authorisation is sought in ...
Breaking Medicine Technology:Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3IGI Laboratories, Inc. Announces Seventh ANDA Submission Of 2015 2Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2
... RDEA806, Demonstrated No Reproductive Toxicity in ... Preclinical Study -, - RDEA427 ... with Potential ... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced preclinical data on its ...
... of Inhaled ... Treprostinil, ... ) and its wholly-owned subsidiary,Lung Rx, Inc. today announced that data ... treprostinil,were reported at the American Thoracic Society (ATS) meeting in Toronto,Ontario. ...
Cached Medicine Technology:Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 2Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 3Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 6
(Date:9/4/2015)... ... 04, 2015 , ... The Schmidt National Law Group filed an Essure® lawsuit ... Schmidt National Law Group, a leading firm in mass-tort litigation, has filed a lawsuit ... Essure, Inc., and other Bayer affiliates for injuries alleged to have been caused by ...
(Date:9/4/2015)... , ... September 04, 2015 , ... After wearing the ... desperate need of new apparel. In an effort to assist the team, the Jones ... launched a charity drive to raise funds for the new uniforms. , As is ...
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of mind ... home is quite common. Mold can grow anywhere - on carpet, clothing, food, paper, ... for excessive moisture and water in the home is key to preventing mold growth, ...
(Date:9/4/2015)... ... ... are looking for a quick and convenient way to produce a hot remedy for colds. ... a quick and simple way to brew a hot cup of cold remedy when desired. ... they enhance comfort and health. The invention features a novel design that is lightweight, compact ...
(Date:9/4/2015)... ... 2015 , ... Having access to a doctor can sometimes be a challenge ... unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to those ... solution to alleviate this problem has recently presented itself, the new telemedicine platform and ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3
... winter diaper rash and predicts a moderate to severe 2008/2009 ... 2 /PRNewswire/ -- For the parents ... mean cute little red outfits, cute little red button noses, ... about their baby,s skin health until sunscreen season comes around ...
... Don,t let snow shoveling ruin your winter wonderland , ... shoveling tends to be an unpleasant task -- this mundane seasonal ... to the back, shoulder muscles if shovelers do not take the ... (AAOS) ( www.aaos.org ) has recommendations to help you stay ...
... Expand to 70 Cities and Regions by 2010 , ... first investment of a new $44 million initiative, the Robert Wood ... nine communities across the country that will serve as leading sites ... epidemic. , , Healthy Kids, ...
... the December 1, 2008, issue of Clinical Cancer ... Cancer Research, show lapatinib benefits women with HER2-positive breast ... who express EGRF alone derive no incremental benefit. In ... as much as 10 percent prevents some people from ...
... DIEGO, Dec. 2 Stroller Strides , the country,s ... announced that Pampers , a leader in baby ... premier sponsor for 2009. , , The ... toddlers and moms. , , "We are ...
... Efficiency by Automating Access Management for 8,000 Users ... Mass., Dec. 2 Courion(R) Corporation , leaders ... Senior Living, the nation,s largest owner and operator of ... to deliver and manage secure access to enterprise applications ...
Cached Medicine News:Health News:Photos: Heads Up, Parents: Get to the Bottom of Winter Diaper Rash 2Health News:Photos: Heads Up, Parents: Get to the Bottom of Winter Diaper Rash 3Health News:Photos: Heads Up, Parents: Get to the Bottom of Winter Diaper Rash 4Health News:Let it Snow, Let it Snow, Let it Snow 2Health News:Let it Snow, Let it Snow, Let it Snow 3Health News:Let it Snow, Let it Snow, Let it Snow 4Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 4Health News:HER2 levels may aid in treatment selection for metastatic breast cancer 2Health News:Stroller Strides(R) Signs Pampers(R) as Premier Sponsor for 2009 2Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 2Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 3
... Sun Med TruFlow™ Oxygen flowmeter with a ... warranty covering calibration and manufacturing defects. A ... meet most needs. Also available with all ... power take-off and double unit configurations. Our ...
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
... flowmeter with a Lexan®inner calibrated flow tube ... manufacturing defects. A wide range of configurations ... available with all popular inlet connections, a ... unit configurations. Our extra large knob coupled ...
... adults, the entire series of time-tested Timeter® ... the needs of care providers and patients ... accuracy. You can see it in the ... performance, year after year. Every Timeter® Classic ...
Medicine Products: